Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2010-10-26 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT reports sustained improvement from DIABECELL NZ Trial 3 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a company announcement reporting clinical trial results for a medical product (DIABECELL) developed by Living Cell Technologies Limited. It provides detailed updates on patient outcomes, dosage groups, and safety information from a Phase II clinical trial. The content focuses on trial progress and clinical data rather than financial results, management changes, or regulatory filings. It is not an earnings release, annual report, or regulatory filing. The document is a detailed company announcement about clinical trial progress and results, which does not fit into financial or governance categories but is a typical corporate announcement of operational progress. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other specific categories.
2010-10-26 English
Annual Report to shareholders 43 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2009–2010' and contains detailed sections typical of an annual report, including Chairman's Report, CEO's Report, Directors' Report, Auditor's Independence Declaration, Corporate Governance Statement, and comprehensive financial statements such as Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows, Notes to the Financial Statements, Directors’ Declaration, and Independent Audit Report. The length of the document (15,000 characters) and the presence of substantive financial data and management commentary confirm it is a full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2010
2010-10-17 English
Notice of Annual General Meeting/Proxy Form 10 pages ?Kb
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for Living Cell Technologies Limited, specifying the date and location of the AGM. It includes agenda items typical for an AGM notice such as consideration of the financial report for the year ended 30 June 2010, remuneration report for the same period, and resolutions for re-election of directors. The document does not contain the actual financial statements or detailed financial data but rather serves as a notice to shareholders about the meeting and the items to be discussed and voted on. It also references the availability of the 2010 Annual Report on the company's website, indicating this document is not the report itself but a meeting notice. Therefore, this document fits the category of AGM Information (AGM-R).
2010-10-17 English
LCT BIO Investor Forum Presentation 25 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation from LCT Health, focusing on their lead product DIABECELL, clinical trial data, development milestones, commercialisation plans, and therapeutic pipeline. It includes forward-looking statements, product descriptions, clinical trial results, and strategic plans. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. The content is typical of an investor presentation aimed at providing comprehensive information about the company's products, pipeline, and future prospects to investors. The document length (15,000 characters) and detailed content support this classification. Therefore, the most appropriate filing type is Investor Presentation (IP).
2010-10-06 English
LCT Managing Director to speak at American Investor Forum 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement about the Managing Director speaking at an investor forum, discussing ongoing clinical trials and future milestones. It contains no financial statements, detailed financial data, or regulatory filings. It is a news or event announcement rather than a formal financial or regulatory report. The content focuses on a presentation event and clinical trial updates, not on financial results or governance changes. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) as a miscellaneous company announcement.
2010-10-04 English
Final Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and options of a director who has ceased to be a director, including dates and specific share and option holdings. This is a report of personal share transactions and interests by a company director. The document length is short (2620 characters) and it is not an announcement of a report publication but a direct disclosure of director's share interests. Therefore, it fits the category of Director's Dealing (DIRS).
2010-09-23 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.